Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Abstract Nowadays, Artificial Intelligence (AI) and machine learning (ML) have successfully
provided automated solutions to numerous real-world problems. Healthcare is one of the …

Abstract α-Synuclein aggregates constitute the pathology of Lewy body (LB) disease. Little is
known about the effects of LB pathology in preclinical (presymptomatic) individuals, either as …

There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …

The world's population is aging, bringing about an ever‐greater burden of mental disorders
in older adults. Given multimorbidities, the mental health care of these people and their …

With an increasingly aging population, health care providers will treat a higher number of
patients with cognitive impairment. Identifying cognitive impairment and intervening early …

Depression with an estimated prevalence of 35% is a frequent manifestation of dementia
with Lewy bodies (DLB), having negative effects on cognitive performance and life …

More than 50 million people have various forms of cognitive impairment basically caused by
neurodegenerative diseases, such as Alzheimer's, Parkinson's, and cerebrovascular …

Importance Psychotic symptoms greatly increase the burden of disease for people with
neurodegenerative disorders and their caregivers. Cholinesterase inhibitors (ChEIs) may be …

Patients who have dementia with Lewy bodies and Alzheimer's disease show early
degeneration of the cholinergic nucleus basalis of Meynert. However, how white matter …